How Healthy Gut Microbiota Can Give CAR T-Cell Recipients a Leg Up
Researchers at the European Hematology Association 2026 Congress highlighted that a diverse gut microbiome, especially the presence of *Akkermansia muciniphila*, improves response and survival for patients receiving CD19‑directed CAR T‑cell therapy for lymphoma and myeloma. Broad‑spectrum antibiotics commonly administered before and after CAR T are linked to poorer overall survival and increased neurotoxicity. Ongoing biobanking and mouse‑model work suggest that restoring beneficial microbes—potentially via fecal microbiota transplantation—could enhance CAR T efficacy. Clinicians are urged to mitigate antibiotic impact while awaiting tailored microbiome‑based interventions.
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
Emerging research highlights oxidative stress as a pivotal upstream driver of vitiligo, linking deficient antioxidant enzymes to melanocyte destruction. Clinical data indicate that antioxidant agents—such as vitamins C/E, alpha‑lipoic acid, and select botanicals—produce meaningful repigmentation only when combined with narrow‑band...
Simple 3-Marker Index May Flag CKM Syndrome Risk Before Costly Disease Progression
A new study in *Diabetology & Metabolic Syndrome* shows that the cholesterol‑HDL‑glucose (CHG) index predicts the onset, stage‑wise progression, and adverse outcomes of cardiovascular‑kidney‑metabolic (CKM) syndrome. Analyzing 370,916 UK Biobank participants and 8,494 Chinese CAD patients, researchers found each standard‑deviation...
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
Hospital‑owned specialty pharmacies are emerging as a solution to the nation’s pharmacy deserts, which affect roughly 48.4 million Americans. By embedding outpatient and specialty services within health‑system walls, hospitals can provide convenient, affordable medication access and coordinate care across the treatment...
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
Trilliant Health’s new claims analysis shows that more than half of patients on GLP‑1 receptor agonists now carry a diagnosis tied to a newly approved or investigational indication, reflecting the class’s rapid expansion beyond diabetes. Patient numbers surged 635.6% from...
Lower In-Hospital Mortality Linked to In-Hospital Statin Exposure
A retrospective study of 545 patients aged 75 and older admitted to an acute geriatric ward found that in‑hospital statin exposure was linked to significantly lower mortality. Only 23.5% of patients received a statin on day two of admission, yet...
Ziftomenib Plus 7+3 Yields Strong Responses in NPM1-Mutated, KMT2A-Rearranged AML: Eunice S. Wang, MD
Ziftomenib combined with standard 7+3 intensive chemotherapy produced an overall response rate of roughly 93% in a frontline cohort of 99 newly diagnosed AML patients with NPM1 mutations or KMT2A rearrangements. Complete remission or CR with partial hematologic recovery reached...
AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD
Artera’s multimodal AI (MMAI) model was directly compared with the Oncotype DX Recurrence Score in a real‑world cohort of HR+/HER2‑negative early‑stage breast cancer. In patients with intermediate RS (11‑25), the AI split 66 % into low‑risk and 34 % into high‑risk groups,...
Hepatitis B Re-Engagement Hinges on How Systems Find Patients: Helen Nde, MPH
A scoping review of 11 hepatitis B re‑engagement programs found re‑engagement rates ranging from 2% in the Netherlands to 100% in Australia and Ireland, highlighting the impact of outreach strategy. Active, in‑person outreach—often via peer navigators—produced the highest success, while passive,...
Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy
Shields Health Solutions announced a partnership with Baptist Health to open an integrated specialty pharmacy inside Baptist MD Anderson Cancer Center in Jacksonville. The new Baptist Specialty Pharmacy will initially serve rheumatology patients, with oncology services slated to launch soon,...
Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management
Deuruxolitinib, a JAK1/2 inhibitor approved in 2024, is dosed at 8 mg twice daily and achieved a SALT score < 20 in 24 weeks, roughly three months sooner than baricitinib. The trial showed a mid‑30% response rate, positioning it as the fastest‑acting JAK inhibitor...
Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata
Baricitinib’s pivotal phase 3 trial in severe alopecia areata (SALT>50) showed that roughly 30% of patients on the 4 mg dose achieved a SALT score below 20 after 36 weeks, while the 2 mg dose lagged considerably. The drug carries the class‑wide JAK‑inhibitor...
Efgartigimod Effective in Broad Subsets of Patients With gMG
The phase‑3 ADAPT trial showed that efgartigimod markedly improves symptoms in generalized myasthenia gravis (gMG) across a wide patient spectrum. In the study’s 167 participants, 63.8% of those receiving efgartigimod met the primary MG‑ADL responder criteria versus 30.2% on placebo....
Cardiorenal Benefits of SGLT2 Inhibitors Beyond Diabetes: Sandra Chaparro, MD
SGLT2 inhibitors are being repositioned as cardio‑renal protective agents for chronic kidney disease (CKD) patients, regardless of diabetes status. Clinical evidence shows they lower cardiovascular events, delay dialysis and improve survival, even in individuals with eGFR as low as 20 mL/min/1.73 m²....
Every Health Care Occupation Is Scarcer in Rural America
A new cross‑sectional analysis of 2019‑2023 ACS data shows rural America employs 44% fewer patient‑facing health‑care workers per 10,000 residents than urban areas. The shortfall is most acute among highly trained clinicians—psychologists are 74% less represented and physicians operate at...